11 Apr 2013 14:21
For immediate release | 11 April 2013 |
ABCAM PLC
("Abcam" or "the Company")
Directors' dealings
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, has today been notified that on 11 April 2013, Jim Warwick, a Director of the Company, exercised share options over 191,600 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") of which 175,010 share options had an exercise price of 62.4 pence per share and 16,590 at 0.2 pence per share.
Mr Warwick subsequently sold 191,600 Ordinary Shares at a price of 426p per Ordinary Share. Following these transactions, Mr Warwick's total interest in the Company is 2,942,269 Ordinary Shares of 0.2 pence each, representing approximately 1.48% of the Company's issued share capital.
On the same day, Jeff Iliffe, a Director of the Company, exercised share options over 127,255 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") of which 22,255 share options had an exercise price of 62.4 pence per share and 105,000 at 0.2 pence per share.
Mr Iliffe subsequently sold 112,255 Ordinary shares at a price of 426p per Ordinary Share and transferred 15,000 Ordinary Shares to his wife, Keren Williams. Following these transactions, Mr Iliffe's total interest in the Company is 39,469 Ordinary Shares of 0.2 pence each, representing approximately 0.02% of the Company's issued share capital.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 680 staff across its eight operating companies.
Abcam now has an online catalogue of over 117,000 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.